Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04762719 · ClinicalTrials.gov registry record · Phase 2
PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT04762719: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT04762719 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04762719, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Macrophage-driven immune dysregulation has been shown to be involved in pathophysiology of diabetic gastroparesis. Currently, there are no non-invasive ways to study macrophage activation in humans. The researchers are trying to determine the utility of 11C-ER176 based PET-CT scanning to determine pro-inflammatory macrophage activation in gastric wall of patients with diabetic gastroparesis.
Interventions
- DRUG PET/CT Scan with 11C-ER176
- DIAGNOSTIC_TEST Core biopsy of gastric muscle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-05-10 |
| Est. Completion | 2022-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04762719
The ClinicalTrials.gov registry entry for NCT04762719 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PET/CT Scan with 11C-ER176 is the first listed.
NCT04762719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04762719 about?
NCT04762719 is a clinical study titled "PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis". Macrophage-driven immune dysregulation has been shown to be involved in pathophysiology of diabetic gastroparesis. Currently, there are no non-invasive ways to study macrophage activation in humans. The researchers are trying to determine the utility of 11C-ER176 based PET-CT scanning to determine p...
What is the current status of trial NCT04762719?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-05-10. Estimated completion is 2022-03-31.
What interventions are being tested in trial NCT04762719?
The interventions under investigation include: PET/CT Scan with 11C-ER176 (DRUG), Core biopsy of gastric muscle (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04762719?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.